Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease
about
sameAs
Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned ratsDrug and gene delivery across the blood-brain barrier with focused ultrasoundTargeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound.Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesisA randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parametersPramipexole for the treatment of early Parkinson's disease.Dopaminergic substitution in Parkinson's disease.Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson's disease: implications for patients.D2 receptor block abolishes θ burst stimulation-induced neuroplasticity in the human motor cortexHuman cognitive flexibility depends on dopamine D2 receptor signaling.Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function.Solid Microneedles for Transdermal Delivery of Amantadine Hydrochloride and Pramipexole Dihydrochloride.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's diseaseLevodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsUpdate on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.Punishment-induced behavioral and neurophysiological variability reveals dopamine-dependent selection of kinematic movement parameters.The indirect pathway of the nucleus accumbens shell amplifies neuropathic painMotor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Dissociable fronto-striatal effects of dopamine D2 receptor stimulation on cognitive versus motor flexibility.Drug interactions at the blood-brain barrier: fact or fantasy?Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties.The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational studyIPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.How should we treat a patient with early Parkinson's disease?Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.IPX066: a novel carbidopa-levodopa extended-release formulation.ADMET considerations for restless leg syndrome drug treatments.Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review.Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?The role of subcutaneous infusion of apomorphine in Parkinson's disease.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease.Green tea polyphenols and their potential role in health and disease.Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.A review of current and novel levodopa formulations for the treatment of Parkinson's disease.Novel Approaches to Optimization of Levodopa Therapy for Parkinson's Disease.Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.
P2860
Q27310170-EB457094-C1A3-435E-AEE8-C7450B39A64FQ28080611-18A2694D-568C-4F83-BF7B-A7CA5683AB14Q30277809-96F0A610-5278-4B08-A9CC-2504321E1065Q33589580-9AB87F69-726C-4308-85CB-437494242E52Q34071690-876F2BDB-6BA8-433D-A49E-47F1896B0AF1Q34630735-6006F6AF-35DD-46A9-88A3-4F60DBC7324AQ34974788-E29F6D2D-3F63-4526-82DD-5F7D44AC1F38Q35006707-8E074199-6821-4DEB-9BD1-5724E1295374Q35171292-8718D041-6FFA-4E28-8E9A-C55FD272B61CQ35534224-647E662E-2FF5-4A56-8FD6-68024896D28CQ35640441-0165A523-7E3C-4E7E-A5F5-7B30887FB268Q35794829-F01A8CC6-3E78-430A-A677-80B10DB1B49AQ36061821-B50BBF0E-602F-4544-AF2C-403A9F9D86CBQ36143799-BB67ABEC-B3AC-4B99-A268-BC249074BB1DQ36361513-C0F709C0-0947-4541-AA01-9A138BA3F71DQ36484966-65ACD009-6DC3-4549-AC84-51C53F48FE74Q36903819-FC09B393-04DB-4CE1-B0E9-84018F54E7E2Q36958717-35372D57-24FE-4370-B925-3BCD27E5238AQ37115650-E3119AA6-DC26-4FFB-BB9A-943ECA3ECA24Q37227887-212ED7D0-7524-4FFA-930C-EC84EDFEF0B7Q37362486-3536E982-072B-4E84-8284-8BB41D4736EFQ37418049-4B6EA4FE-7A30-440F-BA12-CBD6377CA393Q37432045-AA865D48-D8E7-4ED9-BE39-2EDB4D62DA24Q37544096-5F30475F-18BA-4AC8-A634-834F4E2A853EQ37775098-91ABFD92-8F4C-4FC7-804F-3A2F5A5E4FE8Q37776519-CD6453AE-9D40-4948-AAE5-DC0B2F891EB3Q37979870-4C2FDC45-1204-430C-BCD7-0A687DE84FCEQ38027180-BE3D7495-E3CE-4C47-94EC-713D9617BF3DQ38156172-66324EE3-DEBA-44CF-A553-93EF6B36EC6EQ38156422-DB60E906-3FA7-4D88-A031-03CCE9E9F897Q38219351-D96C2286-D2ED-4248-92F5-37E1256D1381Q38223072-373FA04C-6F0B-427B-9401-957E191AB44FQ38242390-CF47F90C-FE07-4B85-8920-03CECE8876EDQ38361898-29A183BC-BC36-4055-A8A6-81F276574750Q38545255-7107F946-A1F3-4505-B2BC-ACE871446E42Q38675921-4C426206-B701-45DB-801A-7B934295B0B4Q38703346-B671E5B5-1589-4023-95E6-55C53AB93258Q38740274-1414FBE1-DA86-477A-BB73-C17FC1D7E995Q38742792-92AE1036-488F-4022-B8C5-AED4F63C9FB4Q38822548-FCDFC1D4-FCB8-4C56-8A5C-8BCFB66ECA4B
P2860
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease
description
2002 nî lūn-bûn
@nan
2002 թուականին հրատարակուած գիտական յօդուած
@hyw
2002 թվականին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@ast
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@en
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@nl
type
label
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@ast
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@en
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@nl
prefLabel
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@ast
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@en
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@nl
P2093
P2860
P921
P1476
Clinical pharmacokinetic and p ...... eatment of Parkinson's disease
@en
P2093
Dirk Deleu
Margaret G Northway
Yolande Hanssens
P2860
P304
P356
10.2165/00003088-200241040-00003
P407
P577
2002-01-01T00:00:00Z
P5875
P6179
1043829394